CureVac N.V. (CVAC)
$4.66+0.00%Close
SELLRECOVERY · day 5
Key stats
- Market cap
- $1.0B
- Beta
- 1.84
- P/E (TTM)
- 4.36
- 1W
- +7.87%
- 1M
- -8.98%
- vs SPY 1W
- +7.45%
- vs SPY 1M
- -11.05%
Industry peers
FMP comparable companies · ranked by market cap
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 3$17.88+0.56%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BRECOVERYQ 8$28.14-2.35%
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.98-0.34%
- NVAXBUYNovavax, Inc.$2.1BBULLQ 10$12.75-0.71%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 17$16.99-2.59%
- INBXSELLInhibrx Biosciences Inc.$1.4BCRISISQ 33$95.01-4.72%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-1.50%
- TRMLTourmaline Bio, Inc.$1.2B$47.98
- NKTRSELLNektar Therapeutics$1.2BCRISISQ 12$41.17-3.23%
- IMTXSELLImmatics N.V.$996MCRISISQ 6$7.43-2.96%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on CVAC?
- LOPJLB’s latest quantitative signal on CureVac N.V. (CVAC) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is CVAC in?
- CureVac N.V. (CVAC) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does CureVac N.V. (CVAC) do?
- CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, …